Chimiothérapie néoadjuvante et cancers du sein avancés ou inflammatoires à Yaoundé (Cameroun)

Journal africain du cancer / African Journal of Cancer 08/2011; 3(3):175-179. DOI: 10.1007/s12558-011-0165-x

ABSTRACT Le but de cette étude était de relever les facteurs limitant la pratique de la chimiothérapie néoadjuvante dans le traitement
des cancers du sein avancés ou inflammatoires en milieu africain au sud du Sahara. Il s’agit d’une étude prospective transversale
dans laquelle l’équipe médicale s’était proposée d’administrer une chimiothérapie avant le traitement de tous les cancers
du sein avancés ou inflammatoires venus pour traitement chirurgical. Sur les 35 malades incluses, la chimiothérapie néoadjuvante
avait été refusée d’emblée par 6 patientes (17,14%), prescrite chez 29 malades (88,8 % des cas), administrée chez 10 patientes
(28,57 %), interrompue chez 11 patientes (31,4 % des cas) pour cause de coût élevé, d’effets néfastes ou de durée longue.
Elle n’avait pas été débutée pour évolution rapide de la tumeur dans six cas. L’étude recommande une prescription optionnelle
de la chimiothérapie néoadjuvante, en milieu africain subsaharien, aux malades présentant un cancer avancé ou inflammatoire
du sein, en tenant compte des limites de cette thérapie, des formes cliniques à évolution rapide et du consentement des patientes.

The aim of this study was to evaluate the limiting factors in the practice of neoadjuvant chemotherapy in the treatment of
advanced or inflammatory breast cancer in an African sub-Saharan context. In this prospective cross-sectional study, the medical
team had proposed to administer neoadjuvant chemotherapy to all patients presenting with an operable advanced or inflammatory
breast cancer. Out of 35 female patients retained, 6 patients (17.14%) refused to undergo preoperative chemotherapy. Twenty-nine
patients were prescribed for neoadjuvant chemotherapy (88.8%). The treatment was administered to 10 patients (28.57%), and
it was interrupted in 11 cases (31.4%) because of cost, side effects or long duration. The treatment was not started in six
patients because of a rapid growth of the tumour. The study recommends an optional prescription of neoadjuvant chemotherapy
to African patients presenting with an advanced or inflammatory breast cancer, taking into account the limitations of the
therapy, the clinical stage of the tumour and consent of the patients.

Mots clésCancer du sein avancé–Chimiothérapie néoadjuvante–Afrique subsaharienne
KeywordsAdvanced breast cancer–Neoadjuvant chemotherapy–Sub-Saharan Africa

Download full-text


Available from: Joseph Marie Mendimi Nkodo, Feb 25, 2014
102 Reads
  • [Show abstract] [Hide abstract]
    ABSTRACT: Currently, preoperative chemotherapy is the standard of care in locally advanced breast cancer to achieve local tumour downsizing in order to make surgery possible. Since the early 1980s, the role of preoperative chemotherapy in early stage (or operable) breast cancer has been the subject of study. Potential advantages are early introduction of systemic therapy, determination of chemosensitivity, reduction of tumour volume and downstaging of surgical requirement. Concerns exist about local control after downsized surgery and the delay of local treatment in patients with tumours resistant to chemotherapy. To assess the effectiveness of preoperative chemotherapy in women with operable breast cancer when compared to postoperative chemotherapy. The Specialised Register maintained by the Editorial Base of the Cochrane Breast Cancer Group was searched on 4th of August 2005. Randomised trials comparing preoperative chemotherapy with postoperative in women with operable breast cancer. Studies were assessed for eligibility and quality, and data were extracted by two independent review authors. Hazard ratios were derived for time-to-event outcomes directly or indirectly using the methods described by Parmar. Relative risks were derived for dichotomous outcomes. Meta-analyses were performed using fixed effect model. We identified 14 eligible studies which randomised a total of 5,500 women. Median follow-up ranged from 18 to 124 months. Eight studies described a satisfactory method of randomisation.Data, based on 1139 estimated deaths in 4620 women available for analysis, show equivalent overall survival rates with a HR of 0.98 (95% CI, 0.87 to 1.09; p, 0.67; no heterogeneity). Preoperative chemotherapy increases breast conservation rates, yet at the associated cost of increased loco regional recurrence rates. However, this rate was not increased as long as surgery remains part of the treatment even after complete tumour regression (HR, 1.12; 95% CI, 0.92 to 1.37; p, 0.25; no heterogeneity. Preoperative chemotherapy was associated with fewer adverse effects. Pathological complete response is associated with better survival than residual disease (HR, 0.48; 95% CI, 0.33 to 0.69; p, < 10-4). This review suggests safe application of preoperative chemotherapy in the treatment of women with early stage breast cancer in order to down-stage surgical requirement, to evaluate chemosensitivity and to facilitate translational research.
    Cochrane database of systematic reviews (Online) 04/2007; 2(2):CD005002. DOI:10.1002/14651858.CD005002.pub2 · 6.03 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: PST (primary systemic therapy) represents the standard treatment of care for patients with LABC (locally advanced breast cancer). There is also an emerging role of PST in the treatment of operable breast cancer. In both situations, clinical and pathological responses, in particular when complete, are good predictors of outcome. Identifying the factors predicting response to PST would help clinicians of selecting the most appropriate treatment. There is thus a need for clinical and molecular factors predictive of response. Unfortunately, none of the molecular markers identified in breast tumors is recommended for a use in routine, with the exception of ER and HER2 respectively predictors of response to hormone therapy and Herceptin. New technologies like DNA microarrays are likely to provide in a next future surrogate markers of response to PST in Breast Cancer.
    Pathologie Biologie 05/2006; 54(4):209-214. DOI:10.1016/j.patbio.2004.11.001 · 1.20 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: Neoadjuvant (primary systemic) treatment is the standard treatment for locally advanced breast cancer and a standard option for primary operable disease. Because of new treatments and new understandings of breast cancer, however, recommendations published in 2003 regarding neoadjuvant treatment for operable disease required updating. Therefore, a second international panel of representatives of a number of breast cancer clinical research groups was convened in September 2004 to update these recommendations. As part of this effort, data published to date were reviewed critically and indications for neoadjuvant treatment were newly defined.
    Journal of Clinical Oncology 05/2006; 24(12):1940-9. DOI:10.1200/JCO.2005.02.6187 · 18.43 Impact Factor
Show more